Verici Dx completes WRAP Retail Offer and raises additional gross proceeds

VRCI

Verici Dx Plc (LON:VRCI) has confirmed the result of its WRAP Retail Offer at the issue price of 0.35 pence per share, following the announcements made on 8 June 2026. The Company has raised aggregate gross proceeds of approximately £0.19 million pursuant to the WRAP Retail Offer in addition to the previously announced Placing. Accordingly, the Company will issue a total of 53,345,832 WRAP Retail Offer Shares.

In total, the Placing and the WRAP Retail Offer has raised gross proceeds of approximately £2.6 million for the Company, via the Placing of 700,000,000 Placing Shares and the 53,345,832 WRAP Retail Offer Shares.

For the avoidance of doubt, the WRAP Retail Offer is not part of the Placing. The issue of the WRAP Retail Offer Shares is conditional upon:

  • the passing of certain resolutions to be put to shareholders of Verici Dx plc at a General Meeting, which is expected to be held at Shoosmiths LLP’s London office at 1 Bow Churchyard, London EC4M 9DQ at 11.30 a.m. on 22 June 2026; and
  • the new Ordinary Shares being admitted to trading on AIM.

Terms used but not defined in this announcement have the same meaning as set out in the Company’s announcement released at 7am on 8 June 2026.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Verici Dx completes WRAP Retail Offer and raises additional gross proceeds

Verici Dx has completed its WRAP Retail Offer, raising approximately £0.19 million in additional gross proceeds and increasing total proceeds to about £2.6 million.

Verici Dx publishes Circular and Notice of General Meeting

Verici Dx has published a circular convening a general meeting on 22 June 2026 to seek authority to issue new ordinary shares on a non-pre-emptive basis following its recent fundraising.

Verici Dx strengthens clinical case for kidney transplant risk testing

Verici Dx has strengthened the clinical evidence behind its pre-transplant kidney rejection risk test, supporting its investor case in precision transplant diagnostics.

Verici Dx launches £200,000 WRAP Retail Offer

Verici Dx has opened a WRAP Retail Offer to raise up to £200,000 through new ordinary shares priced at 0.35 pence each, alongside its recently announced £2.5 million placing.

Verici Dx raises £2.5m through placing

Verici Dx has completed a placing of 700 million shares at 0.35p each, raising gross proceeds of about £2.5 million to support its organ transplant diagnostics business.

Verici Dx secures CPT PLA code for Protega and publishes PTRA study

Verici Dx has received a CPT PLA code for its Protega test and published analysis showing PTRA could deliver major U.S. healthcare savings in kidney transplant care.

Search